医学
持续植物状态
金刚烷胺
唑吡坦
溴隐亭
随机对照试验
意识
巴氯芬
意识水平
警觉
多巴胺能
麻醉
药理学
神经科学
最小意识状态
多巴胺
心理学
内科学
催乳素
受体
激素
兴奋剂
失眠症
标识
DOI:10.1016/j.pmr.2023.06.023
摘要
Pharmacologic treatment of disorders of consciousness remains a critical but challenging task for clinicians. Amantadine has been shown to promote the rate of neurologic recovery for patients with traumatic disorders of consciousness when administered between 4 and 16 weeks, as demonstrated by a well-designed randomized control trial . While there are no large, randomized controlled trials to support the use of other dopaminergic medicines (bromocriptine, levodopa , apomorphine), there is a large body of literature implicating their role in improving alertness and responsiveness in disorders of consciousness. Zolpidem can increase the level of consciousness in a small subset of patients. Zolpidem and intrathecal baclofen likely increase the level of consciousness via the mesocircuit pathway. Psychostimulant medications can be initiated in patients , even without strong evidence to support their use, as long as basic principles of brain injury medicine are followed, and there are systems in place to evaluate therapeutic response.
科研通智能强力驱动
Strongly Powered by AbleSci AI